Natus Medical Incorporated (NTUS)
Stock Price Chart
Key Info
| Market Cap | 614.86M |
| Revenue (ttm) | 449.04M |
| Net Income (ttm) | 10.73M |
| Shares Out | 33.80M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 5, 2020 |
| Last Price | $18.19 |
| Previous Close | $17.52 |
| Change ($) | 0.67 |
| Change (%) | 3.82% |
| Day's Open | 17.52 |
| Day's Range | 17.52 - 18.39 |
| Day's Volume | 428,930 |
| 52-Week Range | 17.37 - 34.89 |
More Stats
| Market Cap | 614.86M |
| Enterprise Value | 624.49M |
| Earnings Date (est) | Oct 21, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 33.80M |
| Float | 33.26M |
| EPS (basic) | 0.31 |
| EPS (diluted) | -0.42 |
| FCF / Share | 1.91 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | 10.49% |
| Payout Ratio | n/a |
| Shares Short | 995,306 |
| Short Ratio | 2.87 |
| Short % of Float | 2.91% |
| Beta | 0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | 9.53 |
| PS Ratio | 1.37 |
| PB Ratio | 1.58 |
| Revenue | 449.04M |
| Operating Income | 18.72M |
| Net Income | 10.73M |
| Free Cash Flow | 64.49M |
| Net Cash | -9.64M |
| Net Cash / Share | -0.29 |
| Gross Margin | 66.50% |
| Operating Margin | 4.17% |
| Profit Margin | 2.20% |
| FCF Margin | 14.36% |
| ROA | 0.74% |
| ROE | -0.32% |
| ROIC | 5.50% |
Analyst Summary
Analyst Consensus: Hold
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 495 | 531 | 501 | 382 | 376 | 356 | 344 | 292 | 233 | 218 |
| Revenue Growth | -6.73% | 5.97% | 31.18% | 1.6% | 5.63% | 3.41% | 17.73% | 25.5% | 6.63% | - |
| Gross Profit | 292 | 304 | 281 | 235 | 228 | 214 | 202 | 163 | 131 | 130 |
| Operating Income | -15.67 | -24.56 | 8.72 | 55.26 | 53.47 | 45.85 | 34.66 | 5.11 | -10.33 | 17.93 |
| Net Income | -15.67 | -22.94 | -20.29 | 42.59 | 37.92 | 32.48 | 23.15 | 3.82 | -11.18 | 11.94 |
| Shares Outstanding | 33.70 | 33.11 | 32.56 | 32.46 | 32.35 | 31.50 | 29.99 | 29.03 | 28.57 | 28.09 |
| Earnings Per Share | -0.47 | -0.69 | -0.62 | 1.29 | 1.14 | 1.00 | 0.75 | 0.13 | -0.39 | 0.41 |
| EPS Growth | - | - | - | 13.16% | 14% | 33.33% | 476.92% | - | - | - |
| Operating Cash Flow | 60.06 | 33.02 | 19.73 | 72.69 | 36.85 | 42.14 | 36.80 | 19.39 | 22.75 | 11.46 |
| Capital Expenditures | -5.33 | -7.88 | -4.07 | -3.19 | -4.07 | -4.24 | -1.83 | -2.25 | -4.18 | -4.15 |
| Free Cash Flow | 54.73 | 25.15 | 15.66 | 69.50 | 32.78 | 37.90 | 34.97 | 17.15 | 18.57 | 7.30 |
| Cash & Equivalents | 63.30 | 56.37 | 88.95 | 248 | 82.47 | 66.56 | 56.11 | 23.06 | 32.82 | 29.39 |
| Total Debt | 72.59 | 104 | 154 | 140 | - | - | 38.02 | 32.86 | 0.90 | 0.89 |
| Net Cash / Debt | -9.29 | -48.10 | -65.33 | 108 | 82.47 | 66.56 | 18.09 | -9.80 | 31.92 | 28.50 |
| Assets | 623 | 638 | 710 | 649 | 479 | 435 | 429 | 392 | 315 | 331 |
| Liabilities | 206 | 240 | 288 | 232 | 88.79 | 82.11 | 121 | 123 | 56.53 | 66.98 |
| Book Value | 416 | 398 | 422 | 417 | 391 | 353 | 308 | 269 | 258 | 264 |
Company Profile
Company Details
| Full Name | Natus Medical Incorporated |
| Country | United States |
| Employees | 1,484 |
| CEO | Jonathan A. Kennedy |
Stock Information
| Ticker Symbol | NTUS |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NASDAQ: NTUS |
Description
Natus Medical Incorporated provides medical device solutions focusing on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and services used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; balance assessment systems to evaluate patients with balance disorders; head-cooling products for the treatment of brain injury in newborns; and incubators to control the newborn's environment. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, and governmental agencies. The company was founded in 1987 and is headquartered in Pleasanton, California.